Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.
Aged
Antigens, CD
Biomarkers, Tumor
Breast Neoplasms
/ blood supply
Disease-Free Survival
Elastin
/ metabolism
Humans
Immunohistochemistry
Ki-67 Antigen
Lymphocyte Subsets
/ pathology
Lymphocytes, Tumor-Infiltrating
/ pathology
Macrophages
/ pathology
Middle Aged
Neoplasm Recurrence, Local
Neovascularization, Pathologic
Prognosis
Receptor, ErbB-2
Retrospective Studies
Tumor Microenvironment
breast cancer
mammography screening
prognosis
stromal elastosis
tumor-associated macrophages
tumor-infiltrating lymphocytes
vascular invasion
Journal
The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
25
03
2021
received:
13
12
2020
accepted:
05
05
2021
pubmed:
3
6
2021
medline:
16
2
2022
entrez:
2
6
2021
Statut:
ppublish
Résumé
The tumor microenvironment plays a critical role in breast cancer progression. Here, we investigated tumor-infiltrating lymphocytes (TILs) and associations with macrophage numbers, tumor stromal elastosis, vascular invasion, and tumor detection mode. We performed a population-based retrospective study using data from The Norwegian Breast Cancer Screening Program in Vestfold County (2004-2009), including 200 screen-detected and 82 interval cancers. The number of TILs (CD45+, CD3+, CD4+, CD8+, and FOXP3+) and tumor-associated macrophages (CD163+) was counted using immunohistochemistry on tissue microarray slides. Lymphatic and blood vessel invasion (LVI and BVI) were recorded using D2-40 and CD31 staining, and the amount of elastosis (high/low) was determined on regular HE-stained slides. High numbers of all TIL subsets were associated with LVI (p ≤ 0.04 for all), and high counts of several TIL subgroups (CD8+, CD45+, and FOXP3+) were associated with BVI (p ≤ 0.04 for all). Increased levels of all TIL subsets, except CD4+, were associated with estrogen receptor-negative tumors (p < 0.001) and high tumor cell proliferation by Ki67 (p < 0.001). Furthermore, high levels of all TIL subsets were associated with high macrophage counts (p < 0.001) and low-grade stromal elastosis (p ≤ 0.02). High counts of CD3+, CD8+, and FOXP3+ TILs were associated with interval detected tumors (p ≤ 0.04 for all). Finally, in the luminal A subgroup, high levels of CD3+ and FOXP3+ TILs were associated with shorter recurrence-free survival, and high counts of FOXP3+ were linked to reduced breast cancer-specific survival. In conclusion, higher levels of different TIL subsets were associated with stromal features such as high macrophage counts (CD163+), presence of vascular invasion, absence of stromal elastosis, as well as increased tumor cell proliferation and interval detection mode. Our findings support a link between immune cells and vascular invasion in more aggressive breast cancer. Notably, presence of TIL subsets showed prognostic value within the luminal A category.
Identifiants
pubmed: 34076969
doi: 10.1002/cjp2.226
pmc: PMC8363927
doi:
Substances chimiques
Antigens, CD
0
Biomarkers, Tumor
0
Ki-67 Antigen
0
Elastin
9007-58-3
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-527Informations de copyright
© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.
Références
Integr Biol (Camb). 2015 Oct;7(10):1120-34
pubmed: 25959051
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Cancer Res. 2006 Feb 15;12(4):1168-74
pubmed: 16489070
Breast Cancer Res. 2011;13(6):227
pubmed: 22078026
PLoS One. 2014 Dec 12;9(12):e115103
pubmed: 25501357
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Acta Oncol. 2007;46(6):792-7
pubmed: 17653902
Pathologe. 2018 Nov;39(6):520-531
pubmed: 30327858
Breast Cancer Res Treat. 2011 Dec;130(3):725-34
pubmed: 21892702
Eur J Surg Oncol. 2017 Jul;43(7):1258-1264
pubmed: 28214052
PLoS One. 2014 Nov 06;9(11):e112121
pubmed: 25375149
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Semin Cancer Biol. 2012 Oct;22(5-6):455-61
pubmed: 22627188
Curr Mol Biol Rep. 2017 Dec;3(4):218-229
pubmed: 29430386
Diagn Pathol. 2014 Dec 19;9:230
pubmed: 25522915
Am J Clin Pathol. 2019 Oct 7;152(5):656-665
pubmed: 31305879
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Oncol Lett. 2019 Feb;17(2):2177-2186
pubmed: 30675282
J Med Screen. 2016 Jun;23(2):89-97
pubmed: 26582492
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Expert Opin Biol Ther. 2008 Dec;8(12):1897-920
pubmed: 18990077
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Front Oncol. 2017 Aug 03;7:156
pubmed: 28824872
Crit Rev Oncol Hematol. 2014 Feb;89(2):231-41
pubmed: 24075309
Oncotarget. 2015 Oct 27;6(33):34758-73
pubmed: 26416449
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
J R Coll Surg Edinb. 1972 Sep;17(5):315-20
pubmed: 5076399
Breast Cancer. 2017 Jan;24(1):3-15
pubmed: 27138387
Cancer Res. 2001 Mar 1;61(5):2256-60
pubmed: 11280795
BMJ. 2009 Jul 09;339:b2587
pubmed: 19589821
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
Breast Cancer Res. 2021 Feb 18;23(1):27
pubmed: 33602289
Breast Cancer (Auckl). 2017 Sep 25;11:1178223417731565
pubmed: 28979132
J Natl Cancer Inst. 2011 Apr 6;103(7):585-97
pubmed: 21350218
Br J Cancer. 2009 Oct 20;101(8):1338-44
pubmed: 19773756
Future Oncol. 2019 Apr;15(11):1193-1196
pubmed: 30880457
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
BMC Cancer. 2016 Aug 26;16:687
pubmed: 27566250
J Clin Oncol. 2010 Oct 10;28(29):4531-8
pubmed: 20516428
Cancer Treat Rev. 2018 Nov;70:178-189
pubmed: 30227299
Br J Cancer. 2013 Sep 17;109(6):1676-84
pubmed: 23982600
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Breast Cancer Res. 2019 Aug 7;21(1):90
pubmed: 31391067
BMC Med. 2015 Aug 24;13:202
pubmed: 26300242
Am J Clin Oncol. 2013 Jun;36(3):224-31
pubmed: 22495453
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
FASEB J. 1999 Oct;13(13):1743-50
pubmed: 10506577
Clin Transl Oncol. 2016 May;18(5):497-506
pubmed: 26459255
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Neoplasma. 2016;63(5):789-98
pubmed: 27468884
J Clin Pathol. 1997 Aug;50(8):669-73
pubmed: 9301551
Hum Pathol. 2017 Nov;69:72-80
pubmed: 28923419
J Clin Pathol. 2017 Apr;70(4):313-319
pubmed: 27612505
Clin Transl Oncol. 2016 Mar;18(3):251-8
pubmed: 26264497
Cancer Treat Rev. 2012 Dec;38(8):943-55
pubmed: 22651904
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801
pubmed: 21825174
Breast Cancer Res. 2014 Sep 06;16(5):432
pubmed: 25193543
Breast Care (Basel). 2016 Apr;11(2):96-100
pubmed: 27239170
JAMA Oncol. 2017 Nov 9;3(11):e172085
pubmed: 28750133
Cancer Biol Med. 2017 Feb;14(1):1-8
pubmed: 28443199
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Breast Cancer Res. 2013 May 16;15(3):R41
pubmed: 23680223